<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432806</url>
  </required_header>
  <id_info>
    <org_study_id>17-594</org_study_id>
    <nct_id>NCT03432806</nct_id>
  </id_info>
  <brief_title>A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors</brief_title>
  <official_title>Development of Novel Imaging and Laboratory Biomarkers to Monitor the Liver Pre-metastatic Niche and Guide Treatment of Colon Cancer: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore novel ways of diagnosing colon cancer and predicting
      its propensity to spread to other organs such as the liver.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>successful isolation of exosomes</measure>
    <time_frame>1 year</time_frame>
    <description>defined as isolation of at least 5μg of exosomal protein and reported as a binomial proportion with a 95% confidence interval.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Liver Tumors</condition>
  <arm_group>
    <arm_group_label>presumptive Stage II or III colon cancer</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage IV colon cancer with resectable hepatic metastases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage IV colon cancer with unresectable hepatic metastases</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage I colon cancer, pre-neoplastic or benign colon lesions</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood draws</intervention_name>
    <description>Three peripheral venous blood draws (10 mL per draw): in the operating room prior to incision, upon completion of the surgical procedure (within 6hours), and first postoperative clinic visit.</description>
    <arm_group_label>presumptive Stage II or III colon cancer</arm_group_label>
    <arm_group_label>Stage IV colon cancer with resectable hepatic metastases</arm_group_label>
    <arm_group_label>Stage IV colon cancer with unresectable hepatic metastases</arm_group_label>
    <arm_group_label>Stage I colon cancer, pre-neoplastic or benign colon lesions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colectomy or hepatectomy</intervention_name>
    <description>Three small pieces of otherwise &quot;normal-appearing&quot; liver of 0.5-1 cm3 collected intraoperatively from patients in all four groups (including Group D).</description>
    <arm_group_label>presumptive Stage II or III colon cancer</arm_group_label>
    <arm_group_label>Stage IV colon cancer with resectable hepatic metastases</arm_group_label>
    <arm_group_label>Stage IV colon cancer with unresectable hepatic metastases</arm_group_label>
    <arm_group_label>Stage I colon cancer, pre-neoplastic or benign colon lesions</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood and tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        MSK clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be undergoing one of the following procedures as part of their routine
             care in order to meet the inclusion criteria:

               -  Operation for presumed stage I-IV colon cancer including colectomy, hepatectomy,
                  or abdominal surgery (e.g. insertion of HAIP)

               -  Colectomy for presumed benign or pre-malignant colon tumors (e.g. large
                  nonneoplastic polyps or adenomas)

          -  Open, laparoscopic, or robotic resections

          -  ≥18 years old

        Exclusion Criteria:

          -  Extrahepatic CRC metastasis

          -  No preoperative portal venous phase CT scan performed up to two months prior to day of
             surgery Pathology demonstrating a malignant tumor other than colorectal
             adenocarcinoma.

          -  Stage IV colon cancer with resectable hepatic disease undergoing hepatectomy with
             active primary colon tumor still in place (despite chemo-radiation therapy) and no
             plans for colectomy.

          -  Receipt of experimental therapies for colon cancer (e.g. checkpoint inhibitors or
             novel targeted agents). Of note, approved targeted agents (such as anti-angiogenic
             agents, EGFR inhibitors etc) are not an exclusion criterion.

          -  History of non-colonic malignancy w/in 5 years (except non-melanomatous skin cancer)

          -  Colon cancer with microsatellite instability (MSI-high) if known preoperatively

          -  Known hereditary colon cancer syndrome such as familial adenomatous polyposis (FAP) or
             hereditary nonpolyposis colorectal cancer (HNPCC)

          -  Known liver disease (e.g. non-alcoholic steatohepatitis, cirrhosis, viral or other
             form of hepatitis, etc)

          -  INR &gt;2 or known clotting factor deficiency

          -  Anticipated need for full anticoagulation during hospitalization

          -  Receipt of medications that increase significantly the risk of bleeding after liver
             biopsy (at the surgeon‟s discretion)

          -  Intraoperative discovery of pathology that precludes the planned surgical resection or
             liver biopsy, or makes resection futile (such as peritoneal carcinomatosis or other
             extrahepatic metastatic disease)

          -  Operating surgeon deems research interventions to be more than a minimal risk for the
             patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D'Angelica</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael D'Angelica, MD</last_name>
    <phone>212-639-3226</phone>
    <email>dangelim@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Wieser, MD</last_name>
    <phone>212-639-6698</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael D'Angelica, MD</last_name>
      <phone>212-639-3226</phone>
    </contact>
    <contact_backup>
      <last_name>Martin Weiser, MD</last_name>
      <phone>212-639-6698</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tissue samples</keyword>
  <keyword>17-594</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

